Dyne Therapeutics (NASDAQ:DYN) Earns Buy Rating from Chardan Capital

Dyne Therapeutics (NASDAQ:DYN)‘s stock had its “buy” rating reissued by analysts at Chardan Capital in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $50.00 price target on the stock. Chardan Capital’s target price points to a potential upside of 64.96% from the company’s current price.

DYN has been the topic of several other research reports. Oppenheimer reissued an “outperform” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a research report on Tuesday, September 3rd. Stifel Nicolaus boosted their target price on Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Morgan Stanley increased their price target on Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. StockNews.com cut Dyne Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 16th. Finally, JPMorgan Chase & Co. lowered shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and cut their target price for the stock from $43.00 to $35.00 in a research report on Thursday, October 24th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $51.40.

Dyne Therapeutics Stock Performance

Dyne Therapeutics stock opened at $30.31 on Wednesday. The firm has a 50 day moving average price of $32.58 and a two-hundred day moving average price of $35.08. Dyne Therapeutics has a 52-week low of $9.76 and a 52-week high of $47.45. The firm has a market cap of $3.04 billion, a price-to-earnings ratio of -8.51 and a beta of 1.10.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.25). As a group, equities research analysts predict that Dyne Therapeutics will post -2.99 EPS for the current fiscal year.

Insiders Place Their Bets

In other Dyne Therapeutics news, Director Dirk Kersten sold 23,671 shares of the company’s stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $35.35, for a total transaction of $836,769.85. Following the transaction, the director now owns 99,652 shares in the company, valued at approximately $3,522,698.20. This represents a 19.19 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO John Cox purchased 32,000 shares of Dyne Therapeutics stock in a transaction dated Wednesday, September 4th. The stock was bought at an average price of $33.04 per share, with a total value of $1,057,280.00. Following the completion of the purchase, the chief executive officer now directly owns 8,000 shares of the company’s stock, valued at approximately $264,320. This trade represents a -133.33 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 158,975 shares of company stock valued at $5,693,789. 20.77% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Dyne Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. FMR LLC raised its stake in shares of Dyne Therapeutics by 69.7% in the third quarter. FMR LLC now owns 9,026,697 shares of the company’s stock worth $324,239,000 after buying an additional 3,707,734 shares during the period. RA Capital Management L.P. purchased a new stake in Dyne Therapeutics in the 1st quarter worth $140,666,000. Vanguard Group Inc. lifted its position in shares of Dyne Therapeutics by 47.7% in the first quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company’s stock valued at $97,669,000 after acquiring an additional 1,110,629 shares in the last quarter. Janus Henderson Group PLC boosted its stake in shares of Dyne Therapeutics by 23,512.0% in the first quarter. Janus Henderson Group PLC now owns 2,675,240 shares of the company’s stock worth $75,915,000 after acquiring an additional 2,663,910 shares during the period. Finally, Artal Group S.A. grew its position in shares of Dyne Therapeutics by 24.6% during the first quarter. Artal Group S.A. now owns 1,517,960 shares of the company’s stock worth $43,095,000 after purchasing an additional 300,000 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.